Company / Interest Expense
ELITE PHARMACEUTICALS INC /NV/ Interest Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$128.2K
FY2024
5-year range
$128.2K / $1.1M
FY2020-FY2024
Trend
-78.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense has fluctuated over the past 9 years, ranging from $128,234 in FY2024 to $1M in FY2022.
Based on SEC 10-K filings.
$128,234 in FY2024 with a 5-year CAGR of -18.5%.
Improved from $1M to $128,234 over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -12.6%
- 5-Year CAGR
- -18.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -18.5%, indicating a declining trend.
- In FY2024, interest expense decreased 78.2% year-over-year.
- Peak interest expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $128.2K | -78.2% |
| FY2023 | $588.6K | -47.1% |
| FY2022 | $1.1M | +480.1% |
| FY2021 | $191.8K | -26.1% |
| FY2020 | $259.6K | -27.1% |
| FY2019 | $355.9K | -3.6% |
| FY2018 | $369.2K | +10.0% |
| FY2017 | $335.5K | +40.8% |
| FY2016 | $238.2K | -15.1% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026